261 related articles for article (PubMed ID: 28902675)
1. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept.
Riazi S; Kraeva N; Hopkins PM
Anesthesiology; 2018 Jan; 128(1):168-180. PubMed ID: 28902675
[TBL] [Abstract][Full Text] [Related]
2. Episodic RYR1-Related Crisis: Part of the Evolving Spectrum of RYR1-Related Myopathies and Malignant Hyperthermia-Like Illnesses.
Dowling JJ; Riazi S; Litman RS
A A Pract; 2021 Jan; 15(1):e01377. PubMed ID: 33512901
[No Abstract] [Full Text] [Related]
3. Oral Dantrolene Reduces Myalgia and Hyperckemia in a Child with RYR1-Related Exertional Myalgia/Rhabdomyolysis.
de Lima Silva EV; Donis KC; Machado FRC; Simão Medeiros L; Aschoff CAM; de Souza CFM; Poswar FO; Saute JAM
J Neuromuscul Dis; 2023; 10(6):1145-1149. PubMed ID: 37781817
[TBL] [Abstract][Full Text] [Related]
4. Genetic specification of malignant hyperthermia susceptibility is warranted for assessing fatigue, depression, and exercise intolerance.
Finsterer J; Scorza FA; Scorza CA
Braz J Anesthesiol; 2023; 73(6):829-830. PubMed ID: 37532110
[No Abstract] [Full Text] [Related]
5. Malignant Hyperthermia: A Review.
Mullins MF
J Perianesth Nurs; 2018 Oct; 33(5):582-589. PubMed ID: 30236564
[TBL] [Abstract][Full Text] [Related]
6. Updated guide for the management of malignant hyperthermia.
Riazi S; Kraeva N; Hopkins PM
Can J Anaesth; 2018 Jun; 65(6):709-721. PubMed ID: 29600483
[TBL] [Abstract][Full Text] [Related]
7. Incidence of malignant hyperthermia in patients undergoing general anesthesia: Protocol for a systematic review and meta-analysis.
In J; Ahn EJ; Lee DK; Kang H
Medicine (Baltimore); 2017 Dec; 96(49):e9115. PubMed ID: 29245345
[TBL] [Abstract][Full Text] [Related]
8. Malignant hyperthermia: still an issue for neuromuscular diseases?
De Wel B; Claeys KG
Curr Opin Neurol; 2018 Oct; 31(5):628-634. PubMed ID: 30015672
[TBL] [Abstract][Full Text] [Related]
9. Malignant Hyperthermia: A Clinical Review.
Kim KSM; Kriss RS; Tautz TJ
Adv Anesth; 2019 Dec; 37():35-51. PubMed ID: 31677658
[No Abstract] [Full Text] [Related]
10. Malignant Hyperthermia.
Kaur H; Katyal N; Yelam A; Kumar K; Srivastava H; Govindarajan R
Mo Med; 2019; 116(2):154-159. PubMed ID: 31040503
[TBL] [Abstract][Full Text] [Related]
11. Succinylcholine Use and Dantrolene Availability for Malignant Hyperthermia Treatment: Database Analyses and Systematic Review.
Larach MG; Klumpner TT; Brandom BW; Vaughn MT; Belani KG; Herlich A; Kim TW; Limoncelli J; Riazi S; Sivak EL; Capacchione J; Mashman D; Kheterpal S; Kooij F; Wilczak J; Soto R; Berris J; Price Z; Lins S; Coles P; Harris JM; Cummings KC; Berman MF; Nanamori M; Adelman BT; Wedeven C; LaGorio J; McCormick PJ; Tom S; Aziz MF; Coffman T; Ellis TA; Molina S; Peterson W; Mackey SC; van Klei WA; Ginde AA; Biggs DA; Neuman MD; Craft RM; Pace NL; Paganelli WC; Durieux ME; Nair BJ; Wanderer JP; Miller SA; Helsten DL; Turnbull ZA; Schonberger RB;
Anesthesiology; 2019 Jan; 130(1):41-54. PubMed ID: 30550426
[TBL] [Abstract][Full Text] [Related]
12. Pennywise and a Pound Foolish: The Advantage of Dantrolene Nanosuspension (Ryanodex) in the Treatment of Malignant Hyperthermia.
McAvoy JC; Brodsky JB; Brock-Utne J
Anesth Analg; 2019 Dec; 129(6):e201-e202. PubMed ID: 31743207
[No Abstract] [Full Text] [Related]
13. Genetic epidemiology of malignant hyperthermia in the UK.
Miller DM; Daly C; Aboelsaod EM; Gardner L; Hobson SJ; Riasat K; Shepherd S; Robinson RL; Bilmen JG; Gupta PK; Shaw MA; Hopkins PM
Br J Anaesth; 2018 Oct; 121(4):944-952. PubMed ID: 30236257
[TBL] [Abstract][Full Text] [Related]
14. The current status of malignant hyperthermia.
Yang L; Tautz T; Zhang S; Fomina A; Liu H
J Biomed Res; 2019 May; 34(2):75-85. PubMed ID: 32305961
[TBL] [Abstract][Full Text] [Related]
15. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group.
Rüffert H; Bastian B; Bendixen D; Girard T; Heiderich S; Hellblom A; Hopkins PM; Johannsen S; Snoeck MM; Urwyler A; Glahn KPE;
Br J Anaesth; 2021 Jan; 126(1):120-130. PubMed ID: 33131754
[TBL] [Abstract][Full Text] [Related]
16. Understanding malignant hyperthermia: each move forward opens our eyes to the distance left to travel.
Dirksen RT; Allen PD; Lopez JR
Br J Anaesth; 2019 Jan; 122(1):8-9. PubMed ID: 30579410
[No Abstract] [Full Text] [Related]
17. Malignant hyperthermia.
Hopkins PM; Gupta PK; Bilmen JG
Handb Clin Neurol; 2018; 157():645-661. PubMed ID: 30459030
[TBL] [Abstract][Full Text] [Related]
18. Malignant Hyperthermia Update.
Ellinas H; Albrecht MA
Anesthesiol Clin; 2020 Mar; 38(1):165-181. PubMed ID: 32008650
[TBL] [Abstract][Full Text] [Related]
19. Malignant hyperthermia - what do we know in 2019?
Cieniewicz A; Trzebicki J; Mayzner-Zawadzka E; Kostera-Pruszczyk A; Owczuk R
Anaesthesiol Intensive Ther; 2019; 51(3):169-177. PubMed ID: 31493330
[No Abstract] [Full Text] [Related]
20. The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutations.
Knuiman GJ; Küsters B; Eshuis L; Snoeck M; Lammens M; Heytens L; De Ridder W; Baets J; Scalco RS; Quinlivan R; Holton J; Bodi I; Wraige E; Radunovic A; von Landenberg C; Reimann J; Kamsteeg EJ; Sewry C; Jungbluth H; Voermans NC
J Neurol; 2019 Apr; 266(4):876-887. PubMed ID: 30788618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
